By Melissa Easy, Vice President, R&D Solutions, IQVIA Technologies
The COVID-19 global pandemic is impacting every aspect of life as we know it. My own new reality is working from home with two young sons, shifting hour by hour between corporate executive and primary-school educator.
Even as business and personal lives intertwine, the pharmaceutical industry has not been distracted from its calling to defeat COVID-19. Organizations everywhere are rallying to find potential treatments and vaccines, while rethinking business models and supply chains to ensure all treatments, whether already in the market or still in development, continue to reach patients in need.
Our challenges are many. Some sponsors have put recruitment on hold in an attempt to mitigate the spread of COVID-19. Trials are experiencing delays in patient recruitment, data collection, and analysis due to patients being unable or unwilling to visit investigator sites. Yet a commitment to as much continuity as possible is evident across the industry, as we are all acutely aware of the patients that depend on trials for their daily care and future survival.